The Influence of Sex and/or Gender on the Occurrence of Colorectal Cancer in the General Population in Developed Countries: A Scoping Review

Int J Public Health. 2024 Apr 10:69:1606736. doi: 10.3389/ijph.2024.1606736. eCollection 2024.

Abstract

Objective: Gender as the "sociocultural role of sex" is underrepresented in colorectal cancer incidence studies, potentially resulting in underestimated risk factors' consequences and inequalities men/women. We aim to explore how literature focusing on differences between men and women in the incidence of colorectal cancer interprets these differences: through sex- or gender-related mechanisms, or both? Methods: We conducted a scoping review using PubMed and Google Scholar. We categorized studies based on their definitions of sex and/or gender variables. Results: We reviewed 99 studies, with 7 articles included in the analysis. All observed differences between men and women. Six articles examined colorectal cancer incidence by gender, but only 2 used the term "gender" to define exposure. One article defined its "sex" exposure variable as gender-related mechanisms, and two articles used "sex" and "gender" interchangeably to explain these inequalities. Gender mechanisms frequently manifest through health behaviors. Conclusion: Our results underscore the need for an explicit conceptual framework to disentangle sex and/or gender mechanisms in colorectal cancer incidence. Such understanding would contribute to the reduction and prevention of social health inequalities.

Keywords: colorectal cancer; gender; incidence; nursing; sex.

Publication types

  • Review

MeSH terms

  • Colorectal Neoplasms* / epidemiology
  • Developed Countries* / statistics & numerical data
  • Female
  • Health Status Disparities
  • Humans
  • Incidence
  • Male
  • Risk Factors
  • Sex Factors
  • Socioeconomic Factors

Grants and funding

AM is supported by the Gendhi project, funded by the European Research Council (ERC) under the European Union’s Horizon 2020 framework programme for research and innovation under grant agreement n° 856478. SL, PG, and CD are supported by the Ligue contre le Cancer as part of the labelling process.